Cargando…
NICE’s rejection of pembrolizumab for platinum-refractory urothelial carcinoma: is there a greater good?
Anti-PD1 and anti-PDL1 immunotherapy has transformed urothelial carcinoma treatment. Pembrolizumab is the only immunotherapy agent shown to have survival benefit compared with standard chemotherapy after progression on platinum-containing chemotherapy. Initial National Institute for Health and Care...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Nature Publishing Group UK
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7338128/ https://www.ncbi.nlm.nih.gov/pubmed/32632305 http://dx.doi.org/10.1038/s41585-020-0357-1 |